MI-538 is primarily used in research settings to study its potential as a therapeutic agent, particularly in cancer treatment. It functions by targeting specific protein-protein interactions, which are crucial for the survival and proliferation of cancer cells. Researchers are exploring its efficacy in disrupting these interactions to inhibit tumor growth and induce apoptosis in malignant cells. Its application is still in the experimental phase, focusing on understanding its mechanism of action and evaluating its safety and effectiveness in preclinical models. MI-538 holds promise as a novel approach in developing targeted cancer therapies, especially for cancers resistant to conventional treatments.